These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31647951)

  • 21. Plate Reader-Based Analytical Method for the Size Distribution of Submicron-Sized Protein Aggregates Using Three-Dimensional Homodyne Light Detection.
    Fukuhara A; Anzai Y; Osawa K; Umeda M; Minemura H; Shiramizu N; Yokoyama M; Uchiyama S
    J Pharm Sci; 2021 Dec; 110(12):3803-3810. PubMed ID: 34425131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Submicron Particle Counting Methods with a Heat Stressed Monoclonal Antibody: Effect of Electrolytes and Implications on Sample Preparation.
    Stelzl A; Grabarek A; Schneid S; Jiskoot W; Menzen T; Winter G
    J Pharm Sci; 2022 Jul; 111(7):1992-1999. PubMed ID: 35081405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Governing the Accuracy of Subvisible Particle Counting Methods.
    Ríos Quiroz A; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    J Pharm Sci; 2016 Jul; 105(7):2042-52. PubMed ID: 27287519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.
    Krause N; Kuhn S; Frotscher E; Nikels F; Hawe A; Garidel P; Menzen T
    AAPS J; 2021 Jan; 23(1):13. PubMed ID: 33398482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticle tracking analysis of particle size and concentration detection in suspensions of polymer and protein samples: Influence of experimental and data evaluation parameters.
    Gross J; Sayle S; Karow AR; Bakowsky U; Garidel P
    Eur J Pharm Biopharm; 2016 Jul; 104():30-41. PubMed ID: 27108267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Strengths of Total Holographic Video Microscopy in Detecting Sub-Visible Protein Particles in Biopharmaceuticals: A Comparison to Flow Imaging and Resonant Mass Measurement.
    Rahn H; Oeztuerk M; Hentze N; Junge F; Hollmann M
    J Pharm Sci; 2023 Apr; 112(4):985-990. PubMed ID: 36596393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
    Singh SK; Afonina N; Awwad M; Bechtold-Peters K; Blue JT; Chou D; Cromwell M; Krause HJ; Mahler HC; Meyer BK; Narhi L; Nesta DP; Spitznagel T
    J Pharm Sci; 2010 Aug; 99(8):3302-21. PubMed ID: 20310025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of submicron particles on formation of micron-sized particles during long-term storage of an interferon-β-1a solution.
    Bai S; Murugesan Y; Vlasic M; Karpes LB; Brader ML
    J Pharm Sci; 2013 Feb; 102(2):347-51. PubMed ID: 23233283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Particle Techniques for the Characterization of Subvisible Particles From Elastomeric Closure Components.
    Rech J; Fradkin A; Krueger A; Kraft C; Paskiet D
    J Pharm Sci; 2020 May; 109(5):1725-1735. PubMed ID: 32017902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein particulate detection issues in biotherapeutics development--current status.
    Das TK
    AAPS PharmSciTech; 2012 Jun; 13(2):732-46. PubMed ID: 22566174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Submicron Protein Particle Characterization using Resistive Pulse Sensing and Conventional Light Scattering Based Approaches.
    Barnett GV; Perhacs JM; Das TK; Kar SR
    Pharm Res; 2018 Feb; 35(3):58. PubMed ID: 29423663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preanalytical, analytical, and biological variation of blood plasma submicron particle levels measured with nanoparticle tracking analysis and tunable resistive pulse sensing.
    Mørk M; Pedersen S; Botha J; Lund SM; Kristensen SR
    Scand J Clin Lab Invest; 2016 Sep; 76(5):349-60. PubMed ID: 27195974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative Differentiation of Protein Aggregates From Other Subvisible Particles in Viscous Mixtures Through Holographic Characterization.
    Winters A; Cheong FC; Odete MA; Lumer J; Ruffner DB; Mishra KI; Grier DG; Philips LA
    J Pharm Sci; 2020 Aug; 109(8):2405-2412. PubMed ID: 32439328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production.
    Sheth P; Sandhu H; Singhal D; Malick W; Shah N; Kislalioglu MS
    Curr Drug Deliv; 2012 May; 9(3):269-84. PubMed ID: 22283656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Flow Imaging Analysis for Subvisible Particle Characterization in Glatiramer Acetate.
    Levin I; Zigman S; Komlosh A; Kettenring J
    J Pharm Sci; 2015 Nov; 104(11):3977-3983. PubMed ID: 26099719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.
    Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.